July 22 Clinical Quick Takes: Positive psoriasis data for Arcutis; plus Intec and Renovo

ARQ-151 meets Phase IIb endpoint
Arcutis Inc. (Westlake Village, Calif.) said high and low daily doses of ARQ-151 for six weeks met the primary endpoint in a Phase IIb

Read the full 286 word article

How to gain access

Continue reading with a
two-week free trial.